Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp145 | Cancer and bone: basic, translational and clinical | ECTS2013

Synergistic anti-tumour effects on human breast cancer cells by mevalonate pathway inhibitors atorvastatin and zoledronic acid

Gobel Andy , Thiele Stefanie , Rauner Martina , Lorenz C Hofbauer , Tilman D Rachner

Introduction: Bone metastases represent a frequent complication of breast cancer and are characterized by increased tumour-driven activation of osteoclasts and subsequent bone loss. Aminobisphosphonates inhibit osteoclast function and are established therapies of skeletal metastases. Similar to statins, they block the mevalonate pathway and are thought to have direct anti-tumour effects. Here, we report on the anti-tumour potential of a sequential inhibition of the mevalonate ...

ba0005p106 | Cancer and bone: basic, translational and clinical | ECTS2016

The Rho GTPases RhoA and CDC42 mediate apoptosis by a combination of statins and zoledronic acid in human bone-seeking breast cancer cells

Gobel Andy , Thiele Stefanie , Browne Andrew J , Rauner Martina , Hofbauer Lorenz C , Rachner Tilman D

Breast cancer is the most frequent malignancy in women and frequently results in osteolytic bone metastases. Amino-bisphosphonates are a standard bone protective therapy and, similarly to statins, inhibit the mevalonate pathway that is crucial for posttranslational protein modifications (farnesylation and geranylation). Direct anti-tumor effects of amino-bisphosphonates and statins have been suggested but high concentrations are necessary to achieve meaningful effects. Our stu...

ba0005p110 | Cancer and bone: basic, translational and clinical | ECTS2016

Role of the receptors FZD8 and RYK in mediating the anti-tumor effects of WNT5A on prostate cancer cells

Thiele Stefanie , Gobel Andy , Hippauf Sandra , Rachner Tilman , Rauner Martina , Hofbauer Lorenz C

Wnt proteins and their cognate receptors play a significant role in malignant diseases, in particular in prostate cancer (PCa). We previously showed that WNT5A inhibits PCa cell proliferation and induces apoptosis in vitro, leading to reduced PCa growth in vivo. However, the involved receptors remain unknown. Here, we determine the role of two Wnt receptors (FZD8, RYK) and their influence on the WNT5A-induced effects on PCa cells.The ex...

ba0005p102 | Cancer and bone: basic, translational and clinical | ECTS2016

Inhibition of mTOR signaling by everolimus has concurrent anti-tumor and bone-protective effects in murine osteolytic cancer models

Browne Andrew , Kubasch Marie Luise , Gobel Andy , Hadji Peyman , Chen David , Rauner Martina , Rachner Tilman , Hofbauer Lorenz

Clinical data suggest that the mTOR inhibitor everolimus may have bone protective effects in addition to its anti-tumor effects in women with ER+/HER2− metastatic breast cancer receiving hormone-ablative therapies. Based on these findings, we tested the hypothesis, whether everolimus exerts concurrent anti-tumor effects while protecting the skeleton in murine models. Thus, we assessed bone metabolism and anti-tumor effects in osteolytic cancer models upon exposure to eve...

ba0003oc5.4 | Important pathways in bone biology and cancer | ECTS2014

WNT5A has anti-prostate cancer effects and protects against bone metastases

Thiele Stefanie , Gobel Andy , Hippauf Sandra , Rachner Tilman D. , Muders Michael , Fussel Susanne , Bernhardt Ricardo , Jakob Franz , Rauner Martina , Hofbauer Lorenz C.

Prostate cancer (PCa) is the most common cancer type in older men and often metastasizes to bone in advanced stages. Wnt proteins are implicated in carcinogenesis and especially WNT5A has been discussed to influence the clinical outcome of various cancer types, including PCa. In addition, WNT5A stimulates osteogenic differentiation and may thus not only be involved in PCa development, but also in the formation of subsequent skeletal metastasis. Here, we determined the role of ...